When must a research protocol be approved by an Institutional Review Board (IRB) for Good Clinical Practice (GCP) certification?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: May 30, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

From the Guidelines

The correct answer is A. Before the research study can begin. According to Good Clinical Practice (GCP) guidelines, a research protocol must receive approval from a designated Institutional Review Board (IRB) or Ethics Committee before any study activities can commence, as emphasized in a recent statement by the European Association of Cardiovascular Imaging (EACVI) of the ESC 1. This requirement is a fundamental ethical safeguard designed to protect the rights, safety, and well-being of human research participants. The IRB review process ensures that the proposed research meets ethical standards, that risks to participants are minimized, and that the potential benefits justify any risks involved. Key aspects of this process include:

  • Ensuring that appropriate measures are taken to protect the rights, health, and well-being of patients participating in the research
  • Conforming to the Declaration of Helsinki
  • Following good clinical practice (GCP) as the ‘international ethical, scientific and practical standard to which all clinical research is conducted’ Starting research before obtaining IRB approval would constitute a serious violation of GCP principles and could potentially put participants at risk, compromise the validity of the research, and lead to regulatory consequences for investigators and sponsors. This requirement applies to all aspects of the study, including recruitment, screening, and any other study-related procedures, highlighting the importance of IRB approval as a preliminary step in the research process, as outlined in the European Heart Journal 1.

From the Research

Research Protocol Approval

The research protocol must be approved by a designated Institutional Review Board at a specific time. The correct option is:

  • A. Before the research study can begin. This is because, as stated in the study 2, the importance and process of ethical approval is crucial in designing a quantitative research study.

Justification

The study 2 emphasizes the importance of ethical approval in the research process, implying that it should be obtained before the study begins. Although the other studies 3, 4, 5, and 6 do not directly address the timing of Institutional Review Board approval, the general principle of obtaining ethical approval before starting a research study is a fundamental aspect of research ethics.

Options Analysis

  • B. After the first participant is randomized: This option is incorrect because ethical approval is necessary before any participants are involved in the study.
  • C. By the time the last participant has completed the last follow-up visit: This option is also incorrect because ethical approval is required before the study starts, not after it is completed.
  • D. There is no designated time for approval: This option is incorrect because there is a designated time for approval, which is before the research study can begin.

Related Questions

What elements are required for a research misconduct finding in GCP (Good Clinical Practice) certification?
What is the required timeframe for reporting a Serious Adverse Event (SAE) to the local Institutional Review Board (IRB) after becoming aware of the event?
What key principles of human research protections did the Belmont Report of 1979 establish?
Which entities are subject to the Health Insurance Portability and Accountability Act (HIPAA) privacy rule: health plans, health care clearinghouses, or other?
What is not an appropriate response to a protocol violation: reducing sample size, documenting and reporting to Institutional Review Board (IRB), or addressing participant safety concerns?
What clinical, pathological, and molecular characteristics are associated with the addition of anti-Cytotoxic T-Lymphocyte Antigen 4 (CTLA4) therapy in non-small cell lung cancer?
What is not an appropriate response to a protocol violation: reducing sample size, documenting and reporting to Institutional Review Board (IRB), or addressing participant safety concerns?
What is the cause of heel pain localized to the medial tuberosity (medial tuberosity of the calcaneus) for 2 months without any history of injury?
What clinical, pathological, and molecular characteristics are associated with the addition of anti-Cytotoxic T-Lymphocyte Antigen 4 (CTLA4) therapy in non-small cell lung cancer?
What clinical, pathological, and molecular characteristics are associated with the addition of anti-Cytotoxic T-Lymphocyte Antigen 4 (CTLA4) therapy in non-small cell lung cancer?
What are the effects of a Gabapentin (Neurontin) overdose?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.